Free Equity Delivery
Flat ₹10 per Trade in Intraday & F&O
| Review By | Apply | May Apply | Neutral | Avoid | Not Rated |
|---|---|---|---|---|---|
| Count | 0 | 0 | 0 | 0 | 0 |
| % | 0 | 0 | 0 | 0 | 0 |
[Dilip Davda] The company is in a highly competitive and fragmented segment of pharma product distribution with third-party contracts under the B2B model. Its profit margins are non-convincing. Based on super profits the issue appears fully priced. The sustainability of margins is a major concern. There is no harm in skipping this tricky issue that will have a longer gestation period for migration to the main board as post IPO its paid-up equity capital is just under Rs. 1.5 cr. Read detail review...
Remus Pharmaceuticals Limited peer comparison with similar listed entities. (Standalone) (As on March 31, 2022)
| Company Name | EPS (Rs) | NAV (per share) (Rs) | P/E (x) | RoNW (%) |
|---|---|---|---|---|
| EPS Basic | ||||
| Remus Pharmaceuticals Limited | 33.86 | 64.30 | 52.64 | |
| Trident Lifeline Limited | 6.92 | 5.97 | 21.46 | 82.66 |
| Vaishali Pharma Limited | 3.82 | 24.99 | 42.68 | 15.27 |
| Chandra Bhagat Pharma Limited | 1.06 | 35.35 | 99.06 | 2.99 |
Remus Pharmaceuticals IPO Reviews, analysis and views by popular members. Read Remus Pharmaceuticals Ltd. IPO reviews by retail investors to find recommended ipo to buy.
| Review By | Apply | May Apply | Neutral | Avoid |
|---|---|---|---|---|
| Count | 0 | 0 | 0 | 0 |
| % | 0.00 | 0.00 | 0.00 | 0.00 |
| Member | Review |
|---|---|
| No recommendation found. Be the first to post the recommendation. | |
Note:
Useful Articles
RHP